IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by KRS Capital Management LLC

KRS Capital Management LLC lessened its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 9.9% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,765 shares of the medical research company’s stock after selling 195 shares during the period. KRS Capital Management LLC’s holdings in IQVIA were worth $446,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC boosted its holdings in shares of IQVIA by 17.5% in the 4th quarter. Los Angeles Capital Management LLC now owns 118,616 shares of the medical research company’s stock valued at $27,445,000 after buying an additional 17,677 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in IQVIA by 4.0% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,418,392 shares of the medical research company’s stock worth $532,070,000 after purchasing an additional 93,194 shares during the period. Cadian Capital Management LP acquired a new stake in IQVIA during the 4th quarter worth $70,108,000. Nomura Holdings Inc. acquired a new stake in IQVIA during the 4th quarter worth $857,000. Finally, International Assets Investment Management LLC purchased a new position in IQVIA during the 4th quarter worth $13,759,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on IQV shares. Barclays cut their price objective on shares of IQVIA from $275.00 to $255.00 and set an “overweight” rating for the company in a research report on Friday. The Goldman Sachs Group started coverage on shares of IQVIA in a research report on Thursday, June 6th. They set a “buy” rating and a $270.00 price objective for the company. Truist Financial cut their price objective on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Robert W. Baird cut their price target on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a report on Friday, May 3rd. Finally, StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $257.73.

IQVIA Trading Down 0.6 %

Shares of IQV traded down $1.31 during mid-day trading on Friday, hitting $211.44. The company had a trading volume of 5,448,174 shares, compared to its average volume of 1,310,028. The business’s 50-day simple moving average is $223.93 and its 200-day simple moving average is $230.06. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The stock has a market cap of $38.52 billion, a PE ratio of 28.87, a P/E/G ratio of 1.94 and a beta of 1.53.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 EPS for the quarter, beating the consensus estimate of $2.19 by $0.11. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. The firm had revenue of $3.74 billion for the quarter, compared to analyst estimates of $3.69 billion. Sell-side analysts forecast that IQVIA Holdings Inc. will post 10.11 earnings per share for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.